• Prominent urologist and ED specialist A/Prof. Darren Katz joins LTR Pharma's Scientific Advisory Board
• Immediate Past Leader of the Australasian Andrology Special Advisory Group (USANZ) brings deep clinical expertise
• Appointment boosts clinical capabilities and strengthens LTR Pharma's expanding prescriber networks

LTR Pharma Limited (ASX:LTP) has announced that Clinical Associate Professor Darren Katz, a renowned urological surgeon and Medical Director of Men's Health Melbourne, has joined LTR Pharma's Scientific Advisory Board. As a SAB member, A/Prof. Katz will advise the company on its research and development and clinical development activities for SPONTAN® and ROXUS®, its innovative nasal spray treatments for erectile dysfunction. A/Prof. Katz is a Clinical Associate Professor in the Department of Surgery at the University of Melbourne and the Immediate Past Leader of the Andrology Special Advisory Group to the Urological Society of Australia and New Zealand, a position he held for 6 years. He has extensive expertise in erectile dysfunction, male voiding dysfunction, urological prosthetics, reconstructive urology, and male infertility. A/Prof. Katz's clinical experience, academic contributions, and deep understanding of prescriber and patient needs will accelerate LTR Pharma's commercialization strategy. He will serve as an expert consultant specifically for SPONTAN, currently available in Australia through the TGA's Special Access Scheme and Authorised Prescriber Program, and will be instrumental in engaging with international key opinion leaders and expanding prescriber networks.